In Vitro Antifungal Resistance of Candida auris Isolates from Bloodstream Infections, South Africa
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Candida auris is a multidrug-resistant fungal pathogen that is endemic in South African hospitals. We tested bloodstream C. auris isolates that were submitted to a reference laboratory for national laboratory-based surveillance for candidemia in 2016 and 2017.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Surveillance studies have demonstrated that MGX was the most mycologically active agent against over 400 diverse C. auris isolates, including strains which were multi-drug resistant (19, 20).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics
White, T. J., Bruns, T., Lee, S., & Taylor, J. (1990) · PCR Protocols · doi:10.1016/b978-0-12-372180-8.50042-1 · Cited by 36,648
PCR protocols — A guide to methods and applications
U.G. (1990) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(90)90252-7 · Cited by 11,702
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 9×
“Resistant (n= 84) Fluconazole 1 (8) 60 (78) 1 (50) Amphotericin B 0 1 (1) 0 Micafungin 0 0 0 Fluconazole and amphotericin B 12 (92) 7 (9) 0 Fluconazole, amphotericin B, and micafungin 0 2 (3) 0”
BackgroundResultInfluentialSelf-citationChowdhary, A., Prakash, A., Sharma, C., Kordalewska, M., Kumar, A., Sarma, S., Tarai, B., Singh, A., Upadhyaya, G., Upadhyay, S., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx480 · Cited by 577 · cited 4×
“auris isolates collected between 2009 and 2017 reported that 14% were resistant to both azoles and flucytosine, 7% to both azoles and amphotericin B, and 2% to azoles and echinocandins (2).”
BackgroundInfluentialKathuria, S., Singh, P. K., Sharma, C., Prakash, A., Masih, A., Kumar, A., Meis, J. F., & Chowdhary, A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00367-15 · Cited by 532 · cited 2×
“auris isolates are resistant to all classes of systemic antifungal agents in current use for candidemia (9, 10).”
BackgroundChow, N. A., Muñoz, J. F., Gade, L., Berkow, E., Li, X., Welsh, R. M., Forsberg, K., Lockhart, S. R., Adam, R., Alanio, A., et al. (2020) · doi:10.1101/2020.01.06.896548 · Cited by 463
Self-citationMuñoz, J. F., Gade, L., Chow, N. A., Loparev, V. N., Juieng, P., Berkow, E. L., Farrer, R. A., Litvintseva, A. P., & Cuomo, C. A. (2018) · Nature Communications · doi:10.1038/s41467-018-07779-6 · Cited by 458 · cited 4×
“Reference sequences and annotations for these genes were obtained from the susceptible clade I reference strain C. auris B8441 (GenBank accession number PEKT00000000) and the clade III C. auris B11221 isolate (GenBank accession number PGLS00000000) (1, 9).”
BackgroundInfluentialSelf-citationCandida auris : The recent emergence of a multidrug-resistant fungal pathogen
Forsberg, K., Woodworth, K., Walters, M., Berkow, E. L., Jackson, B., Chiller, T., & Vallabhaneni, S. (2019) · Medical Mycology · doi:10.1093/mmy/myy054 · Cited by 421 · cited 1×
“Antifungal resistance seems to be clade specific; clade I, III, and IV isolates may be resistant to multiple antifungal agents, while clade II isolates are generally more susceptible (13, 14).”
BackgroundAntifungal Combinations for Treatment of Cryptococcal Meningitis in Africa
Molloy, S. F., Kanyama, C., Heyderman, R. S., Loyse, A., Kouanfack, C., Chanda, D., Mfinanga, S., Temfack, E., Lakhi, S., Lesikari, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710922 · Cited by 396 · cited 1×
“A combination of amphotericin B and flucytosine is a potent regimen and is known to be efficacious for other serious fungal infections, such as cryptococcal meningitis (21).”
BackgroundMultidrug-resistant endemic clonal strain of Candida auris in India
Chowdhary, A., Anil Kumar, V., Sharma, C., Prakash, A., Agarwal, K., Babu, R., Dinesh, K. R., Karim, S., Singh, S. K., Hagen, F., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-2027-1 · Cited by 373 · cited 1×
“Clade I and III echinocandin-resistant isolates have been reported to have either the S639F or S639Y substitution (7, 14).”
Background
Research works printed but not linked: 1
- Clinical and Laboratory Standard Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA. [Google Scholar]
Cited by
Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents
Jacobs, S. E., Jacobs, J. L., Dennis, E. K., Taimur, S., Rana, M., Patel, D., Gitman, M., Patel, G., Schaefer, S., Iyer, K., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00053-22 · Cited by 190
Rybak, J. M., Barker, K. S., Muñoz, J. F., Parker, J. E., Ahmad, S., Mokaddas, E., Abdullah, A., Elhagracy, R. S., Kelly, S. L., Cuomo, C. A., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.024 · Cited by 120
Self-citationVazquez, J. A., Pappas, P. G., Boffard, K., Paruk, F., Bien, P. A., Tawadrous, M., Ople, E., Wedel, P., Oborska, I., & Hodges, M. R. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01419-22 · Cited by 92
Burrack, L. S., Todd, R. T., Soisangwan, N., Wiederhold, N. P., & Selmecki, A. (2022) · mBio · doi:10.1128/mbio.00842-22 · Cited by 82
Strategies to Prevent Transmission of Candida auris in Healthcare Settings
Ahmad, S., & Asadzadeh, M. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00451-7 · Cited by 77
Candida auris: Epidemiology and Antifungal Strategy
Eix, E. F., & Nett, J. E. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-061523-021233 · Cited by 74
Update on the Pathogenesis, Virulence, and Treatment of Candida auris
Watkins, R. R., Gowen, R., Lionakis, M., & Ghannoum, M. (2022) · Pathogens and Immunity · doi:10.20411/pai.v7i2.535 · Cited by 68
“For example, research on the South African clade (clade III) demonstrates high azole resistance, but lower polyene and echinocandin resistance [71].”
BackgroundEmergence of the novel sixth Candida auris Clade VI in Bangladesh
Khan, T., Faysal, N. I., Hossain, M. M., Mah-E-Muneer, S., Haider, A., Moon, S. B., Sen, D., Ahmed, D., Parnell, L. A., Jubair, M., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03540-23 · Cited by 61
“Since the molecular mecha nism of amphotericin B is not well established, we also investigated known mutations in ERG3 (S58T) and ERG6 (G403T and R97fs) genes involved in ergosterol biosynthetic pathways which are postulated to confer amphotericin B resistance (14, 40).”
BackgroundDeciphering the Mrr1/Mdr1 Pathway in Azole Resistance of Candida auris
Li, J., Coste, A. T., Bachmann, D., Sanglard, D., & Lamoth, F. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00067-22 · Cited by 59
Expert recommendations for prevention and management of Candida auris transmission
Aldejohann, A. M., Wiese‐Posselt, M., Gastmeier, P., & Kurzai, O. (2022) · Mycoses · doi:10.1111/myc.13445 · Cited by 65
Vinayagamoorthy, K., Pentapati, K. C., & Prakash, H. (2022) · Mycoses · doi:10.1111/myc.13447 · Cited by 53
da Silva, K. J. G., Lucini, F., Santos, R., Santos, D. A., Meis, J. F. G. M., Melhem, M. D. S. C., Peres, N. T. A., Bastos, R. W., & Rossato, L. L. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.04.003 · Cited by 56
Siopi, M., Peroukidou, I., Beredaki, M.-I., Spruijtenburg, B., de Groot, T., Meis, J. F. G. M., Vrioni, G., Tsakris, A., Pournaras, S., & Meletiadis, J. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04431-22 · Cited by 47
Update on therapeutic approaches for invasive fungal infections in adults
Boutin, C.-A., & Luong, M. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361231224980 · Cited by 54
Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician
Lamoth, F. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s375625 · Cited by 43
“5% and 4%.(14,15,28,29) Overall, the rate of echinocandin resistance among Candida spp.”
BackgroundMaphanga, T. G., Mpembe, R. S., Naicker, S. D., Govender, N. P., & GERMS-SA, F. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01717-21 · Cited by 42
Self-citationKekana, D., Naicker, S. D., Shuping, L., Velaphi, S., Nakwa, F. L., Wadula, J., Govender, N. P., & GERMS-SA1, F. (2023) · Emerging infectious diseases · doi:10.3201/eid2910.230181 · Cited by 42
Self-citationMunshi, A., Almadani, F., Ossenkopp, J., Alharbi, M., Althaqafi, A., Alsaedi, A., Al-Amri, A., & Almarhabi, H. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.11.021 · Cited by 34
Upc2-mediated mechanisms of azole resistance in Candida auris
Li, J., Aubry, L., Brandalise, D., Coste, A. T., Sanglard, D., & Lamoth, F. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03526-23 · Cited by 33
Siopi, M., Pachoulis, I., Leventaki, S., Spruijtenburg, B., Meis, J. F. G. M., Pournaras, S., Vrioni, G., Tsakris, A., & Meletiadis, J. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.01528-23 · Cited by 34
“…the ERG3 , ERG5 , ERG6 , and/or ERG10 genes, which have been associated with amphotericin B resistance in other Candida spp., have not been previously identified among phenotypi cally amphotericin B-resistant C. auris strains, and thus, resistance could not be verified molecularly (9, 36, 37).”
BackgroundNarayanan, A., Selvakumar, P., Siddharthan, R., & Sanyal, K. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00634-22 · Cited by 36
“their response to various antifungals (15, 20), with drug resistance-associated single”
BackgroundWilliamson, B., Wilk, A. S., Guerrero, K. D., Mikulski, T. D., Elias, T. N., Sawh, I., Cancino-Prado, G., Gardam, D., Heath, C. H., Govender, N. P., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01624-21 · Cited by 30
Self-citationDiagnostic Allele-Specific PCR for the Identification of Candida auris Clades
Carolus, H., Jacobs, S., Lobo Romero, C., Deparis, Q., Cuomo, C. A., Meis, J. F., & Van Dijck, P. (2021) · Journal of Fungi · doi:10.3390/jof7090754 · Cited by 29
“Clade III isolates are most often resistant to fluconazole, but resistance to amphotericin B is rare [2,19].”
BackgroundRaman Metabolomics of Candida auris Clades: Profiling and Barcode Identification
Pezzotti, G., Kobara, M., Nakaya, T., Imamura, H., Fujii, T., Miyamoto, N., Adachi, T., Yamamoto, T., Kanamura, N., Ohgitani, E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911736 · Cited by 31
“auris clinical isolates were reported to exhibit a diversified resistance to multiple drug classes including azoles and polyenes [6,7].”
BackgroundScott, N. E., Erayil, S. E., Kline, S. E., & Selmecki, A. M. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00543-23 · Cited by 30
One species, many faces: The underappreciated importance of strain diversity
Nysten, J. V., Sofras, D., & Dijck, P. V. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1011931 · Cited by 30
“Resistance to fluconazole is common among strains of Clades I and III, whereas amphotericin B resistance is frequent solely for Clade I, and echinocandin resistance is often found within Clade IV isolates [53–55].”
BackgroundThomsen, J., Abdulrazzaq, N. M., Oulhaj, A., Nyasulu, P. S., Alatoom, A. A., Denning, D. W., Dhaheri, F. A. A., Menezes, G. A., Moubareck, C. A., Senok, A. C., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1244358 · Cited by 30
Candida auris: A Systematic Review of a Globally Emerging Fungal Pathogen in Africa
Osaigbovo, I. I., Ekeng, B. E., Davies, A. A., Ebeigbe, E., Bongomin, F., Kanyua, A., Revathi, G., & Oladele, R. O. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad681 · Cited by 30
“Antifungal susceptibility was reported for isolates from Algeria [29], Egypt [30], Nigeria [34], and Kenya [31, 32], with surveillance isolates from South Africa and isolates from a phase 2 clinical trial in South Africa [22, 23, 29].”
BackgroundRamos, L. S., Barbosa, P. F., Lorentino, C. M. A., Lima, J. C., Braga, A. L., Lima, R., Giovanini, L., Casemiro, A. L., Siqueira, N. L. M., da Costa, S. C., et al. (2025) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2025.100354 · Cited by 33
Drug repurposing against Candida auris: A systematic review
Izadi, A., Gharehbolagh, S. A., Sadeghi, F., Talebi, M., Darmiani, K., Zarrinnia, A., Zarei, F., Peymaeei, F., Khojasteh, S., Borman, A. M., et al. (2022) · Mycoses · doi:10.1111/myc.13477 · Cited by 23
The first invasive Candida auris infection in Taiwan
Tsai, Y.-T., Lu, P., Tang, H.-J., Huang, C., Hung, W., Tseng, Y.-T., Lee, K.-M., & Lin, S. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2100280 · Cited by 21
Genomics insights of candidiasis: mechanisms of pathogenicity and drug resistance
Huang, X., Dong, Q., Zhou, Q., Fang, S., Xu, Y., Hu, L., Chen, J., Li, X. Y., Qin, H., Mu, D., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1531543 · Cited by 24
Kurakado, S., Matsumoto, Y., & Sugita, T. (2023) · Medical Mycology · doi:10.1093/mmy/myad108 · Cited by 18
Espinel‐Ingroff, A. (2022) · Journal of Fungi · doi:10.3390/jof8030309 · Cited by 20
“auris 11 FLU: Resistant Cutoff: ≥32 ERG 11: Y132F, VF125AL, K117R, N335S, E343D, NA [55]”
BackgroundEttadili, H., & Vural, C. (2024) · Brazilian Journal of Microbiology · doi:10.1007/s42770-023-01239-0 · Cited by 20
“Indeed, fluconazole resistance in C. auris was associated with different mutations in the ERG11 gene known as amino acid substitutions at some specific positions (e.g., F126T or F126L or V125A in South Africa, Y132F or K143R in India, Y132F in Venezuela) [11, 51, 53, 54].”
InfluentialExploration of novel mechanisms of azole resistance in Candida auris
Li, J., Brandalise, D., Coste, A. T., Sanglard, D., & Lamoth, F. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01265-24 · Cited by 19
Achilonu, C. C., Barwatt, W. J., Kottom, T. J., Oladele, R. O., Ramatla, T. A., & LIMPER, A. H. (2025) · Medical Mycology · doi:10.1093/mmy/myaf107 · Cited by 18
Balla, N., Kovács, F., Balázs, B., Borman, A. M., Bozó, A., Jakab, Á., Tóth, Z., Kobaissi, O., Majoros, L., & Kovács, R. (2022) · Antibiotics · doi:10.3390/antibiotics11111601 · Cited by 16
“Several investigators have proposed combination-based therapeutic approaches using existing drugs to overcome the difficult-to-treat C. auris-related infections, including biofilm associated cases, increasing the likelihood of therapeutic success (Bidaud et al. 2020, Brennan-Krohn et al. 2021, Caballero et al. 2021, N…”
BackgroundResultInfluentialIbe, C., & Pohl, C. H. (2024) · The Lancet Microbe · doi:10.1016/j.lanmic.2024.100996 · Cited by 12
Delma, F. Z., Melchers, W. J. G., Verweij, P. E., & Buil, J. B. (2024) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlae153 · Cited by 12
Current Antifungals and the Developing Pipeline
Johnson, M. D., & Moore, W. J. (2025) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2025.01.001 · Cited by 13
Boyer, J., Hoenigl, M., & Kriegl, L. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2317293 · Cited by 12
“They are fungistatic against Aspergillus spp . and fungicidal against most Candida spp ., including those resistant to fluconazole and have also shown preserved activity against emerging Candida auris [15–17].”
BackgroundSiopi, M., Leventaki, S., Pachoulis, I., Spruijtenburg, B., Meis, J. F. G. M., Pournaras, S., Vrioni, G., Tsakris, A., & Meletiadis, J. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.00399-25 · Cited by 10
“This could be due to the higher MTS MIC values of clade I strains compared to isolates belonging to other clades (modal MIC 2 mg/L versus 0.125–1 mg/L), which is consistent with previous observations using Etest (28, 29).”
InfluentialKordalewska, M., Guerrero, K. D., Mikulski, T. D., Elias, T. N., Garcia‐Rubio, R., Berrío, I., Gardam, D. J., Heath, C. H., Chowdhary, A., Govender, N. P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.22.465535 · Cited by 9
Self-citationDeciphering the multidrug resistance paradigm in Candida auris
Santana, D. J., Cauldron, N. C., Rogers, P. D., & Cuomo, C. A. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01062-24 · Cited by 10
“One study reported missense muta tions in ERG3 and ERG2 from resistant clinical populations, but subsequent work identified the same alleles in drug-susceptible isolates (14, 165).”
Bohner, F., Papp, C., Takács, T., Varga, M., Szekeres, A., Nosanchuk, J. D., Vágvölgyi, C., Tóth, R., & Gácser, A. (2023) · Journal of Fungi · doi:10.3390/jof9121148 · Cited by 10
“While the missense SNP, S58T, is not linked with antifungal resistance [73], nonsense mutation (W182*) can confer a reduction in susceptibility to azoles [38].”
BackgroundYerbanga, I. W., Diallo, S. N., Rouamba, T., Ouédraogo, D. F., Lagrou, K., Oladele, R. O., Gangneux, J., Denis, O., Rodriguez‐Villalobos, H., Montesinos, I., et al. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.121012 · Cited by 9
Yang, J.-X., Ma, G., Li, Y.-T., Shi, Y.-P., & Liang, G.-W. (2024) · Clinics · doi:10.1016/j.clinsp.2024.100497 · Cited by 9
Ibe, C., Otu, A. A., & Pohl, C. H. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2448844 · Cited by 7
“Only five papers [47,52,53,55,56] reported missense mutations in FKS genes but none led to any of the predominant Fks amino acid substitutions (F641S and S643P) in Candida species [69].”
InfluentialA benchmark dataset for validating FKS1 mutations in Candida auris
Misas, E., Parnell, L. A., Rajeev, M., López, L. F., dos Santos, A. R., Mudge, Z. B., Gade, L., Forsberg, K., Lyman, M., Sexton, D. J., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.03147-24 · Cited by 12
“Notably, the D642Y amino acid change was previously reported in three echinocandin-susceptible Clade I isolates collected from three different cases (36).”
Cosio, T., Pedretti, N., Spaggiari, L., Ruda, L. T., Kenno, S., Sabbatini, S., Pistoia, E. S., Comar, M., Monari, C., Ardizzoni, A., et al. (2025) · Journal of Fungi · doi:10.3390/jof11090625 · Cited by 7
“C. auris strains are classified in six distinct clades named after the geographical areas where the strains were first isolated: South Asian (clade I), East Asian (clade II), African (clade III), South American (clade IV), Iran (clade V) and Singapore (clade VI) [9–11].”
Ombajo, L. A., Kanyua, A., Ngugi, R., Malcolm, C., Berkow, E. L., Gade, L., Bancroft, E., Osoro-Mbui, J., Njoroge, R., Juma, P., et al. (2024) · IJID Regions · doi:10.1016/j.ijregi.2024.100460 · Cited by 8
“Similar observations have been made in South Africa, where 91% of C. auris isolates were found to be resistant to at least one antifungal class [ 22 ], with one recent report of an outbreak of C. auris in a neonatal unit in which 6% of the isolates were resistant to amphotericin B and 2.3% of…”
ResultInfluentialOworae, K. O., Rayens, E. A., Chapman, T., Wychrij, D. A., Buzzelli, L., Rabacal, W., & Norris, K. A. (2025) · Vaccines · doi:10.3390/vaccines13101033 · Cited by 5
“These results support the concept that the immunologic range of the NXT-2 vaccine may include geographic areas with different clades or in individuals experiencing infection with multiple clades [45–47].”
Jenkins, L. B., Christian, R., Karaman, B. A., Ghannoum, M. A., & Dousa, K. M. (2025) · ASM Case Reports · doi:10.1128/asmcr.00114-25 · Cited by 7
Luca, D. G. D., Li, X. R., Alexander, D. C., Dingle, T. C., Dufresne, P. J., Hoang, L., Kus, J. V., Sheitoyan-Pesant, C., & Bharat, A. (2025) · Medical Mycology · doi:10.1093/mmy/myaf019 · Cited by 5
Ramli, A. H., Jayathilaka, E. H. T. T., Dias, M. K. H. M., Malek, E. A., Jain, N., An, J., Churchill, D. G., Rukayadi, Y., Swain, P., Kim, C., et al. (2024) · Microbial Pathogenesis · doi:10.1016/j.micpath.2024.106797 · Cited by 4
Orner, E. P., & Thwe, P. M. (2024) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2024.10.005 · Cited by 4
Moreau, J., Noël, T., Point, K., Tewes, F., Deroche, L., Clarhaut, J. A., Fitton‐Ouhabi, V., Cateau, E., Marchand, S., Buyck, J. M., et al. (2024) · Mycoses · doi:10.1111/myc.13704 · Cited by 3
Kwon, Y. J., Kim, H. S., Kim, S. J., Shin, J. H., & Kim, S. H. (2026) · Annals of Laboratory Medicine · doi:10.3343/alm.2025.0664 · Cited by 2
“Clade I C. auris, initially linked to South Asia, is now globally distributed and commonly multidrug-resistant, with approximately 90% of isolates resistant to at least two antifungal classes [1, 3, 8].”
COVID-19 pandemic and the evolving epidemiology of Candidemia: A topic of concern!!!
Rajni, E., Garg, V. K., Vohra, R., Jangid, Y., & Sharma, R. (2022) · Novel Research in Microbiology Journal · doi:10.21608/nrmj.2022.259623 · Cited by 2
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · Wiley eBooks · doi:10.1002/9781683670438.mcm0134 · Cited by 2
Wan, G., Zhang, H., Yang, X. Y., Sun, Q., Wen, C., Hong, F., He, L., Mo, D., Chen, X., Li, Q., et al. (2025) · BMC Microbiology · doi:10.1186/s12866-025-04576-2 · Cited by 2
“The main of Clade II and VI are susceptible to fluconazole [9, 10], whereas Clade I, III, and IV often show resistance mostly due to mutations in the ERG11 gene [10, 11].”
Chowdhury, F., Mah‐E‐Muneer, S., Khan, S., Lyman, M., Mamun, G. M. S., Lockhart, S. R., Habib, Z. H., Rahman, A., Hossain, K., Hassan, M. Z., et al. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.03169-25 · Cited by 1
“Globally, C. auris is classified into six phylogenetic clades, named as South Asian (Clade I), East Asian (Clade II), African (Clade III), South American (Clade IV), Iranian (Clade V), and the recently described Clade VI (17, 38).”
InfluentialNegi, P., Verma, N., Rishi, P., Multani, K., Sharma, M., Kumari, S., & Raj, K. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-04864-z · Cited by 1
“C. auris strains are prevalent, echinocandin-resistant isolates (such as caspofungin) are sporadic (Maphanga et al. 2021 ).”
Lass‐Flörl, C., Steixner, S. J. M., Bauer, A., Meis, J. F. G. M., Colombo, A. L., Cornely, O. A., Chakrabarti, A., Hagen, F., dos Santos, A. R., Seyedmousavi, S., et al. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00263-26 · Cited by 1
Du, X., & Li, L. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1873741 · Cited by 1
Lemes, T. H., Nascentes, J. A. S., Regasini, L. O., Maschio-Lima, T., de Almeida, B. G., Ribeiro, M. D., Pattini, V. C., Mozaner, L. D. Q., Siqueira, J. P. Z., & de Almeida, M. T. G. (2022) · Brazilian Journal of Case Reports · doi:10.52600/2763-583x.bjcr.2023.3.1.24-29 · Cited by 1
Genomic Innovation and Virulence Evolution in the Emerging Human Fungal Pathogen Candida auris
Gifford, H., Rhodes, J. L., Wilson, D., & Farrer, R. A. (2024) · The mycota · doi:10.1007/978-3-031-75666-5_10 · Cited by 2
Mechanisms of Resistance to Antifungal Agents
Perlin, D. S. (2023) · Wiley eBooks · doi:10.1002/9781683674849.mcm0134 · Cited by 1
Resistome and Resistance Mechanisms of Candidozyma Auris Clade IV: A Systematic Review
Bonilla-Caballero, M. A., Álvarez, G., & González, Á. F. (2025) · Current Tropical Medicine Reports · doi:10.1007/s40475-025-00353-3
“The EGR9 gene has also been implicated in azole resistance, although less frequently; in this regard, fluconazole-resistant isolates with genotypes presenting substitutions in M351V and A27T have been described [22].”
van Hofwegen, L. S., Hassnain, M., Balraadjsing, P. P. S., van Dijk, K., Hagen, F., Nizamoğlu, S., & Zaat, S. A. J. (2026) · Journal of Fungi · doi:10.3390/jof12030216
“In particular, isolates from Clades I, III and IV have been reported to have high resistance to at least one of the antifungal classes [12–15].”
Moola, A., Thom, M. G., Finlay, J. M., Rule, R., & Said, M. (2026) · Southern African Journal of Infectious Diseases · doi:10.4102/sajid.v41i1.817
“26,27 For the two echinocandins included in routine testing, micafungin showed a decline in mean MIC values over the study period, while caspofungin demonstrated a similar downward trend.”
Siopi, M., Leventaki, S., Pachoulis, I., Rentoumi, A., Argyris, N., Spruijtenburg, B., Meijer, E. F. J., Meis, J. F. G. M., Pournaras, S., Tsakris, A., et al. (2026) · Journal of Clinical Microbiology · doi:10.1128/jcm.00130-26 · Cited by 1
“The modal SYO MIC observed aligns with previous reports (0.125 mg/L) (31); however, as this study represents the first head-to-head evaluation of SYO and CLSI for this agent in C. auris , the results cannot be directly compared with other data, yet they provide valuable reference for future…”
InfluentialKundu, S., Banerjee, C., & Bhattacharjee, S. G. (2026) · Medical Mycology · doi:10.1093/mmy/myag055
Kumari, S., Rain, Z., Prakash, P., Tilak, R., & Singh, A. K. (2026) · Scientific Reports · doi:10.1038/s41598-026-57636-6
“The antifungal resistance profile of C. auris observed in this study, characterized by high fluconazole resistance and reduced susceptibility to amphotericin B and caspofungin, is consistent with reports from multiple geographic regions 34,35 .”
Validation of molecular detection of Candida auris from wastewater
Stewart, R. M. R., Litvintseva, A. P., Chavez, J., Sexton, D. J., & Lockhart, S. R. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.02508-25
Non-albicans Candida Species: Epidemiology and Antifungal Resistance
Bosan, M. A., Durrani, A. D., Faiz, A., Farooqi, J. Q., & Jabeen, K. (2026) · Current Fungal Infection Reports · doi:10.1007/s12281-026-00542-1
“Echinocandin resistance in C. auris is primarily associated with mutations in FKS1 , which encodes the 1,3-β-D-glucan synthase target of echinocandins (Table 2 ) [ 74 – 76].”
Satia, S., Pfeiffer, J., Kılıç, A., Furuya, E. Y., Smithgall, M. C., MANSUKHANI, M. M., Hsiao, S., Shi, J., Kumar, R., Green, D. A., et al. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.01695-26
“Additionally, resistance to one echinocandin does not necessarily correlate with resistance to all (33).”
Metadata
- Authors
- Maphanga, T. G., Naicker, S. D., Kwenda, S., Muñoz, J. F., van Schalkwyk, E., Wadula, J., Nana, T., Ismail, A., Coetzee, J., Govind, C., Mtshali, P. S., Mpembe, R. S., & Govender, N. P.
- Affiliations
- National Health Laboratory Service (ZA)
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
- National Institute for Communicable Diseases, Centre for Healthcare-Associated Infections, Antimicrobial Resistance, and Mycoses, National Health Laboratory Service, Johannesburg, South Africa
- AMPATH National Laboratory Service, Centurion, South Africa
- Lancet Laboratories (ZA)
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2021-08-17
- Volume
- 65
- Issue
- 9
- Pages
- e0051721-e0051721
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC8370198
- OpenAlex
- W3178182121
- Cited by
- 78
- References
- 38
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 19 · 2023: 12 · 2022: 15 · 2021: 4
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- doi.org/10.1128/ASMCopyrightv2 (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida auris, antifungal resistance, bloodstream infection, azole resistance, polyene resistance, echinocandin resistance, resistance gene mutations, in vitro susceptibility, South Africa
- MeSH terms
- Antifungal Agents, Candida, Humans, Microbial Sensitivity Tests, South Africa, Fluconazole, Drug Resistance, Fungal, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.